Japan PPI inflation slips to 11-mth low in July
WEIFANG, CHINA - Hongli Group Inc. (NASDAQ:HLP) announced Tuesday that it received a deficiency notice from Nasdaq on July 10, 2025, for failing to maintain the minimum bid price requirement of $1.00 per share. The stock currently trades at $0.66, down about 48% year-to-date according to InvestingPro data.
The notice follows a 30 consecutive business day period between May 27 and July 9, 2025, during which the company’s closing bid price fell below the threshold required for continued listing on The Nasdaq Capital Market. InvestingPro analysis shows the stock has experienced significant volatility, trading between $0.63 and $2.12 over the past 52 weeks, with multiple indicators suggesting challenging market conditions.
Hongli Group has been granted a compliance period of 180 calendar days, until January 6, 2026, to regain compliance with the minimum bid price requirement. The company can achieve compliance if its closing bid price reaches or exceeds $1.00 per share for a minimum of 10 consecutive business days during this period.
If unable to meet the requirement within the initial timeframe, Hongli may be eligible for an additional 180-day compliance period, provided it meets other Nasdaq Capital Market listing standards and submits written notice of its intention to cure the deficiency.
The company stated it will monitor its share price and evaluate available options to regain compliance, which could include implementing a reverse stock split. Any such split would need to be completed at least ten business days before the January 6, 2026 deadline.
The deficiency notice has no immediate effect on Hongli Group’s listing status on the Nasdaq Capital Market.
Hongli Group is a manufacturer of cold roll formed steel profiles for machinery and equipment across various sectors including mining, construction, agriculture, and transportation. The company, currently valued at $50.5 million in market capitalization, generates annual revenue of $14.11 million. InvestingPro analysis indicates the stock is currently overvalued, with additional insights available through their comprehensive financial health assessment tools.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.